Adaptive Biotechnologies president and COO Julie Rubinstein sells $928,891 in stock

Julie Rubinstein, President and Chief Operating Officer of Adaptive Biotechnologies, sold a substantial portion of company shares worth $928,891 from October 30 to November 3, 2026. This followed the exercise of stock options for an equivalent amount valued at $432,706. The stock had grown by 78% over the past six months, although current analysis suggests the shares are trading above their Fair Value.

Rubinstein initiated selling 9,486 shares at prices between $26.20 and $27.07, followed by an additional 2,395 shares priced from $27.21 to $27.98. She also exercised options for 11,881 shares at $12.14 per share. Further sales on November 2 included 9,296 shares at prices ranging from $24.88 to $25.86, and 2,585 shares between $25.91 and $26.81.

She again exercised options for 11,881 shares at $12.14 each. The final reported transactions on November 3 saw her selling 11,881 shares at prices between $25.65 and $26.43, also following option exercises for the same amount. In total, Rubinstein sold 35,643 shares at prices between $25.23 and $27.45 and acquired 35,643 shares through option exercises at $12.14 per share.

All transactions were executed under a Rule 10b5-1 trading plan adopted on November 18, 2025. After these transactions, Rubinstein directly owns 377,802 shares of Adaptive Biotechnologies. The company's stock currently trades at $25.80 with a market capitalization of $4 billion. For further insights into ADPT’s valuation, comprehensive analysis can be found in the detailed Pro Research Report available exclusively on InvestingPro.